Study: Tests Used to Predict Response to PARP Inhibitors Yield... - Ovarian Cancer News Today

kuekuedunia.blogspot.com

Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability to repair their DNA — a status termed “homologous recombination deficiency” (HRD), and likely would respond to treatment with PARP inhibitors — yield inconsistent results, a recent study shows. Study findings were presented in the poster “Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer,” at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held online due to the global pandemic. PARP inhibitors are medications that work by blocking the activity of PARP enzymes, which are involved in DNA repair. By blocking the activity of the enzymes, these agents prevent cancer cells from repairing their DNA, eventually eliminating them. PARP inhibitors tend to be more effective in patients with HRD-positive tumors, meaning those that either have a mutation in BRCA, a DNA repair gene, that impairs its function, or have high genomic instability (high number of genetic mutations). There are several tests that can be used to determine the HRD status or the degree of genomic instability of a tumo

Let's block ads! (Why?)

"used" - Google News
August 04, 2020 at 07:00PM
https://ift.tt/39WgeUl

Study: Tests Used to Predict Response to PARP Inhibitors Yield... - Ovarian Cancer News Today
"used" - Google News
https://ift.tt/2ypoNIZ
https://ift.tt/3aVpWFD

Bagikan Berita Ini